149 related articles for article (PubMed ID: 15825676)
1. Treatment possibilities of Alzheimer's disease.
Miklya I; Gaszner P
Neuropsychopharmacol Hung; 2004 Dec; 6(4):200-9. PubMed ID: 15825676
[TBL] [Abstract][Full Text] [Related]
2. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl And Tocopherol Antioxidative Therapy Of Parkinsonism.
Shoulson I
Ann Neurol; 1998 Sep; 44(3 Suppl 1):S160-6. PubMed ID: 9749589
[TBL] [Abstract][Full Text] [Related]
3. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression.
Gaszner P; Miklya I
Neuropsychopharmacol Hung; 2004 Dec; 6(4):210-20. PubMed ID: 15825677
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
5. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
6. [Clinical pharmacology and therapeutic aspects in certain degenerative neurological diseases].
Maloteaux JM
Bull Mem Acad R Med Belg; 1996; 151(10-11):429-32; discussion 432-4. PubMed ID: 9491620
[TBL] [Abstract][Full Text] [Related]
7. Can we prevent Parkinson's and Alzheimer's disease?
Kedar NP
J Postgrad Med; 2003; 49(3):236-45. PubMed ID: 14597787
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment.
LeWitt PA
J Neural Transm Suppl; 1994; 43():171-81. PubMed ID: 7884399
[TBL] [Abstract][Full Text] [Related]
10. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Youdim MB
Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
[TBL] [Abstract][Full Text] [Related]
11. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of degenerative dementia disorders--who should be treated?].
Hasselbalch SG; Kampmann JP
Ugeskr Laeger; 2009 Mar; 171(10):802-5. PubMed ID: 19265606
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives.
Shimazu S; Miklya I
Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):421-7. PubMed ID: 15093948
[TBL] [Abstract][Full Text] [Related]
14. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
15. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
16. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
17. [Medicinal and chemical approaches to focused search of agents for treatment and therapy of Alzheimer disease].
Bachurin SO
Vopr Med Khim; 2001; 47(2):155-97. PubMed ID: 11450439
[TBL] [Abstract][Full Text] [Related]
18. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease.
Maczurek A; Hager K; Kenklies M; Sharman M; Martins R; Engel J; Carlson DA; Münch G
Adv Drug Deliv Rev; 2008; 60(13-14):1463-70. PubMed ID: 18655815
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease and the 'ABSENT' hypothesis: mechanism for amyloid beta endothelial and neuronal toxicity.
Roy S; Rauk A
Med Hypotheses; 2005; 65(1):123-37. PubMed ID: 15893129
[TBL] [Abstract][Full Text] [Related]
20. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
